Abstract

 

OBJECTIVES

Recurrent laryngeal nerve lymph node dissection (LND) has been incorporated into oesophagectomy for patients with oesophageal squamous cell carcinoma, but with uncertain oncological efficacy.

METHODS

The data of patients with oesophageal squamous cell carcinoma, including who underwent upfront surgery (surgery group) and those who received neoadjuvant therapy followed by surgery (neoadjuvant chemoradiotherapy group), were retrospectively examined. The overall survival (OS) and disease-free survival (DFS) were compared between patients with and without recurrent laryngeal nerve LND.

RESULTS

Among the 312 patients, no significant differences were found in 3-year OS and DFS between patients with and without recurrent laryngeal nerve LND in the entire cohort (OS: 57% vs 52%, P = 0.33; DFS: 47% vs 41%, P = 0.186), or the surgery group (n = 173, OS: 69% vs 58%, P = 0.43; DFS: 52% vs. 48%, P = 0.30) and the neoadjuvant chemoradiotherapy group (n = 139, OS: 44% vs 43%, P = 0.44; DFS: 39% vs 32%, P = 0.27). However, among patients with clinical positive recurrent laryngeal nerve lymph node involvement before treatment, there was significant OS and DFS differences between patients with and without recurrent laryngeal nerve LND (OS: 62% vs 33%, P = 0.029; DFS: 49% vs 26%, P = 0.031).

CONCLUSIONS

Recurrent laryngeal nerve LND is not a significant prognostic factor in patients with oesophageal squamous cell carcinoma; however, it is associated with better outcomes in patients with pre-treatment radiological evidence of recurrent laryngeal nerve lymph node involvement.

中文翻译：

---

食管鳞状细胞癌喉返神经淋巴结清扫术后患者的临床结果

摘要

 

目标

喉返神经淋巴结清扫术（LND）已被纳入食管鳞状细胞癌患者的食管切除术，但肿瘤学疗效尚不确定。

方法

回顾性分析了接受前期手术（手术组）和接受新辅助治疗后手术（新辅助放化疗组）的食管鳞状细胞癌患者的资料。比较有无喉返神经LND患者的总生存期（OS）和无病生存期（DFS）。

结果

在 312 名患者中，在整个队列中，有和没有喉返神经 LND 的患者的 3 年 OS 和 DFS 没有显着差异（OS：57% vs 52%，P  =  0.33；DFS：47% vs 41% , P  =  0.186)，或手术组 ( n  = 173, OS: 69% vs 58%, P  =  0.43; DFS: 52% vs. 48%, P  =  0.30) 和新辅助放化疗组 ( n  = 139, OS：44% 对 43%，P  =  0.44；DFS：39% 对 32%，P  = 0.27)。然而，在治疗前临床阳性喉返神经淋巴结受累的患者中，有和没有喉返神经 LND 的患者的 OS 和 DFS 存在显着差异（OS：62% vs 33%，P  =  0.029；DFS：49% vs 26%，P  =  0.031）。

结论

喉返神经 LND 不是食管鳞状细胞癌患者的重要预后因素；然而，对于有喉返神经淋巴结受累的治疗前放射学证据的患者，它与更好的结果相关。